Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil.
Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Paediatr Perinat Epidemiol. 2020 May;34(3):267-277. doi: 10.1111/ppe.12632. Epub 2020 Jan 22.
Over-the-counter analgesic use during pregnancy, particularly acetaminophen, may be associated with negative developmental outcomes in children.
Estimate associations of prenatal and early-life exposure to acetaminophen in early childhood with cognitive, motor, and language skills in two birth cohorts.
The American Project Viva cohort (1217 mother-child pairs enrolled 1999-2002) assessed cognition at approximately 3 years using the Peabody Picture Vocabulary Test and the Wide Range Achievement of Visual Motor Abilities (WRAVMA). The Brazilian 2015 Pelotas Birth Cohort (3818 mother-child pairs) assessed cognition at 2 years using the INTERGROWTH-21st Neurodevelopment Assessment. We used linear regression to estimate associations of acetaminophen use during pregnancy (Project Viva and Pelotas) and infancy (Project Viva) with children's cognitive scores adjusted for maternal age, pre-pregnancy body mass index, education, parity, race/ethnicity, smoking and alcohol use during pregnancy, depression during pregnancy, antibiotic and ibuprofen use during pregnancy, household income, and child's sex.
In Project Viva, exposure to acetaminophen in both the 1st and 2nd trimester of pregnancy was associated with lower WRAVMA drawing scores (β -1.51, 95% CI -2.92, -0.10). However, in Pelotas, exposure to acetaminophen in both the 1st and 2nd trimester of pregnancy was not associated with INTER-NDA motor scores (β 0.02; 95% CI -0.05, 0.09) and was associated with higher INTER-NDA total scores (β 0.08, 95% CI 0.01, 0.16). Other comparisons did not show evidence for any associations.
Inconsistencies and lack of specificity of the findings did not clarify the research question considering that we still have a large variability and uncertainty to define the risk or safety in the use of acetaminophen related to cognition in early childhood. More studies using better exposure assessment and better confounding variables are needed to clarify these associations.
孕期非处方止痛药的使用,特别是对乙酰氨基酚,可能与儿童发育不良结局有关。
估计在两个出生队列中,儿童早期接触产前和生命早期的对乙酰氨基酚与认知、运动和语言技能的关联。
美国项目 Viva 队列(1999-2002 年招募了 1217 对母婴)使用 Peabody 图片词汇测试和广泛的视觉运动能力成就测试(WRAVMA)大约在 3 岁时评估认知。巴西 2015 年佩洛塔斯出生队列(3818 对母婴)在 2 岁时使用 INTERGROWTH-21st 神经发育评估来评估认知。我们使用线性回归来估计在妊娠(项目 Viva 和佩洛塔斯)和婴儿期(项目 Viva)期间使用对乙酰氨基酚与儿童认知评分的关联,这些评分经过调整,包括母亲年龄、孕前体重指数、教育程度、产次、种族/民族、怀孕期间吸烟和饮酒、怀孕期间抑郁、怀孕期间使用抗生素和布洛芬、家庭收入和儿童性别。
在项目 Viva 中,妊娠 1 期和 2 期接触对乙酰氨基酚与 WRAVMA 绘图得分较低有关(β-1.51,95%CI-2.92,-0.10)。然而,在佩洛塔斯,妊娠 1 期和 2 期接触对乙酰氨基酚与 INTER-NDA 运动评分无关(β0.02;95%CI-0.05,0.09),与 INTER-NDA 总分较高有关(β0.08,95%CI0.01,0.16)。其他比较没有发现任何关联的证据。
由于我们仍然有很大的变异性和不确定性来定义与儿童早期认知相关的使用对乙酰氨基酚的风险或安全性,因此这些发现的不一致性和缺乏特异性并不能澄清研究问题。需要更多使用更好的暴露评估和更好的混杂变量的研究来澄清这些关联。